ClinicalTrials.gg
CompletedNCT02493998Updated Mar 6, 2020

A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

An observational study in Mucopolysaccharidosis Type IIIB, Mucopolysaccharidosis Type 3 B and MPS III B, sponsored by Allievex Corporation. Completed at 8 sites in 8 countries. Open to participants aged 1 Year to 10 Years. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by Allievex Corporation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
22
Ages
1 Year to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Enrollment
13th of 19
22 · median 30
Started
2015
with 2 others
Observational
19 of 43
5 open now
Registered
16th of 43
by date
Lead sponsor
5 of 43
Allievex Corporation

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 13th largest by enrollment of the 19 observational ones that give a count, is one of 3 that started in 2015, is one of 19 observational ones, and was the 16th registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 1 Year to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

Mucopolysaccharidosis type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B) is a severe neurodegenerative disorder. The purpose of this study is to learn more about the health problems in patients with MPS IIIB and how to measure these problems over time. It will particularly look at how the disease develops in young children. This is an observational study, so no experimental drug will be given. The results from this study will help us design future studies to measure whether these health problems get better when we give experimental drug for MPS IIIB.

Read the detailed description

This is a multicenter, multinational, longitudinal, observational study in subjects 1 through 10 years of age who have been diagnosed with MPS IIIB. Data will be prospectively collected from 20 to 30 subjects to understand the clinical progression of MPS IIIB in terms of neurocognitive function, behavior, quality of life, imaging characteristics, genotype, and biochemical markers of disease burden. This information may help inform the design and interpretation of subsequent interventional studies.

03

Conditions studied

  • Mucopolysaccharidosis Type IIIB
  • Mucopolysaccharidosis Type 3 B
  • MPS III B
  • MPS 3 B

Keywords

  • Sanfilippo Syndrome Type B
04

Who can participate

Ages eligible
1 Year to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study Population: Subjects diagnosed with MPS IIIB

Males and females 1 through 10 years of age (ie, until they turn 11) with a documented diagnosis of MPS IIIB are eligible to participate in this observational study. Up to approximately 5 subjects 6 to 10 years old, inclusive, will be enrolled; the remaining subjects will be 1 to 5 years old, inclusive. Additional entry criteria follow.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals eligible to participate in this study must meet all of the following criteria:
  • Has deficient NAGLU enzyme activity at Screening. Blood for NAGLU enzyme activity will be collected and analyzed centrally.
  • Is ≥ 1 and ≤ 10 years of age and has an age-equivalent of ≥ 12 months on the VABS-II
  • DQ ≥ 50 (determined by BSID-III or KABC-II)
  • Has presented with signs/symptoms consistent with MPS IIIB; for individuals who have not presented with signs/symptoms of disease (e.g., siblings of known patients), the determination of eligibility will be at the discretion of the BioMarin medical monitor in conjunction with the site investigator.
  • Written from parent or legal guardian and assent from subject, if required
  • Has the ability to comply with protocol requirements, in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  • Has another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, or hemorrhage) before study entry
  • Requires ventilation support, except for noninvasive support at night
  • Has received stem cell, gene therapy or ERT for MPS IIIB
  • Has for neurosurgery (e.g., congenital heart disease, severe respiratory impairment, or clotting abnormalities)
  • Has contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, or aneurysm clip in the brain)
  • Has a history of poorly controlled seizure disorder
  • Is prone to complications from intraventricular drug administration, including patients with hydrocephalus or ventricular shunts
  • Has received any medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
  • Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's wellbeing or safety, or the interpretability of the subject's clinical data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
22 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Neurocognitive function

    A neurodevelopmental assessment will be performed using standardized developmental tests to provide quantifiable measures of neurocognitive function.

    Time frame: Screening, baseline, and every 12 weeks, for up to 48-96 weeks

  2. Imaging characteristics

    MRI will be used to assess changes in size of various organs affected by the disease, including brain, liver and spleen.

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

  3. Behavioral function

    Disease-related behaviors will be assessed using an MPS III-specific behavior rating scale.

    Time frame: Baseline and every 12 weeks, for up to 48-96 weeks

  4. Hearing

    The function of conductive and sensorineural hearing pathways will be assessed using tympanometry and auditory brainstem response (ABR).

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

  5. Sleep habits

    Patient sleep habits will be assessed using specific questionnaires.

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

  6. Quality-of-life

    Multiple QOL tools will be used to capture physical, mental, and social well-being of the patient as well as to examine the impact of the patient's disease on the parent/guardian and family.

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

  7. Biochemical, Molecular, Cellular and Genetic Markers of Disease Burden

    Blood, urine, and CSF samples will be used to evaluate biochemical, molecular cellular, and genetic/genomic aspects of MPS IIIB.

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

07

Study locations

8 sites
  • Children's Hospital and Research Center Oakland
    Oakland, California 94609, United States
  • Melbourne Children's Trials Centre
    Melbourne, Victoria, Australia
  • Fundacion Cardioinfantil-Instituto de Cardiologia
    Bogota, Colombia
  • University Medical Center Hamburg Eppendorf, Department of Pediatrics
    Hamburg, Germany
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, Spain
  • MacKay Memorial Children's Hospital
    Taipei, Taiwan
  • Gazi University Faculty of Medicine
    Ankara, Turkey
  • Somers Clinical Research Facility, Great Ormond Street Hospital
    London, United Kingdom
08

References and documents

Publications

  • Okur I, Ezgu F, Giugliani R, Muschol N, Koehn A, Amartino H, Harmatz P, de Castro Lopez MJ, Couce ML, Lin SP, Batzios S, Cleary M, Solano M, Peters H, Lee J, Nestrasil I, Shaywitz AJ, Maricich SM, Kuca B, Kovalchin J, Zanelli E. Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB. J Pediatr. 2022 Oct;249:50-58.e2. doi: 10.1016/j.jpeds.2022.06.005. Epub 2022 Jun 13. PubMed 35709957 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Apr 2019, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2015
First posted
Jul 10, 2015
StartActual
Nov 2015
Primary completionActual
Apr 2019
CompletionActual
Apr 2019
Last update
Mar 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02493998
Lead sponsor
Allievex Corporation
Responsible party
Sponsor
First posted
Jul 10, 2015
Start date
Nov 2015
Primary completion
Apr 2019
Completion
Apr 2019
Last update
Mar 6, 2020

Study contacts

Allievex Medical Monitor
study director · Allievex Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion